Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)